300685.SZ
艾德生物
SZSE · Healthcare · C 制造业 · CN
CNY 18.41
−3.05%Year over year
Reported trailing growth
- Revenue
- +3.3%
- EBITDA
- —
- EBIT
- +29.1%
- EPS
- +28.1%
- Free cash flow
- -7.7%
- Operating cash flow
- +1.2%
Forward estimates
Based on analyst estimates
- Revenue
- +13.9%
- EBITDA
- +1.0%
- EPS
- +8.1%
Three-year CAGR
- Revenue
- +12.5%
- EBITDA
- +11.9%
- EBIT
- +13.2%
- Net income
- +11.1%
- EPS
- +10.7%
- Free cash flow
- +60.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026